Literature DB >> 2403484

Beta-lactam regimens for the febrile neutropenic patient.

G P Bodey1, V Fainstein, L S Elting, E Anaissie, K Rolston, N Khardori, H Kantarjian, C Plager, W K Murphy, F Holmes.   

Abstract

A total of 535 evaluable febrile episodes in neutropenic patients were randomly assigned to treatment with ticarcillin-clavulanate plus vancomycin (TV), ceftazidime plus vancomycin (CV), or all three antibiotics (TCV). The TCV regimen was significantly more effective than TV, considering all evaluable episodes, documented infections, gram-negative infections, and infections in patients with persistent severe neutropenia (less than 100 neutrophils/mm3). The results with CV were intermediate between TV and TCV. The toxicities were similar with all three regimens and consisted primarily of skin rashes. The TCV regimen is effective for empiric therapy of fever in neutropenic patients and probably should be utilized in preference to CV or TV, although its superiority over CV in this study was inconclusive.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2403484     DOI: 10.1002/1097-0142(19900101)65:1<9::aid-cncr2820650105>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Comparison of two antibiotic regimens (piperacillin plus amikacin versus ceftazidime plus amikacin) as empiric therapy for febrile neutropenic patients with cancer.

Authors:  J Feliu; A Artal; M González Barón; A Berrocal; I Chacón; M L García de Paredes; E Espinosa; A Ordóñez; P Zamora; J M Montero
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Evolution of the clinical manifestations of infection during the course of febrile neutropenia in patients with malignancy.

Authors:  E C Dompeling; J P Donnelly; J M Raemaekers; S C Deresinski; R Feld; B E De Pauw
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

Review 3.  Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.

Authors:  G Dranitsaris
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

4.  A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients.

Authors:  A A Fauser; E Lang; G Köchling; F D Daschner
Journal:  Infection       Date:  1994 Jul-Aug       Impact factor: 3.553

Review 5.  Outpatient management of febrile episodes in neutropenic cancer patients.

Authors:  E B Rubenstein; K Rolston
Journal:  Support Care Cancer       Date:  1994-11       Impact factor: 3.603

6.  Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.

Authors:  Carmen P Escalante; Mary Ann Weiser; Ellen Manzullo; Robert Benjamin; Edgardo Rivera; Tony Lam; Vi Ho; Rosalie Valdres; Eva Lu Lee; Noemi Badrina; Sally Fernandez; Yvette DeJesus; Kenneth Rolston
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 7.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

Review 8.  Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.

Authors:  Mical Paul; Dafna Yahav; Assaf Bivas; Abigail Fraser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

Review 9.  Community respiratory viral infections in the immunocompromised host: past, present, and future directions.

Authors:  G P Bodey
Journal:  Am J Med       Date:  1997-03-17       Impact factor: 4.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.